mRNA Therapy as a Treatment for CF - Deepika Polineni, MD, MPH

Dr. Deepika Polineni, Assistant Professor of Internal Medicine at the University of Kansas Health System and Associate Adult Program Director for the University of Kansas CF Care Center, provides a comprehensive review of mRNA as a novel therapeutic option for people with CF of all mutation types, and explains the difference between mRNA therapy and gene editing/ gene therapy. Results of the most recent clinical trials evaluating mRNA therapy in CF are also discussed. This presentation was part of CFRI's Virtual 34th National CF Education Conference on July 31, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.